New PET scan could reveal hidden prostate cancer
NCT ID NCT05245006
First seen Jan 10, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This early-phase study tests a new PET imaging agent (89Zr-DFO-YS5) that targets a protein called CD46, found on many aggressive prostate cancer cells. About 30 men with advanced, treatment-resistant prostate cancer will receive the agent and then have PET scans to see if it can accurately detect tumors. The goal is to improve imaging and help develop better treatments for the most dangerous forms of prostate cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.